Avenue Therapeutics reveals Axsome's acquisition of Baergic Bio
Written by Emily J. Thompson, Senior Investment Analyst
Acquisition Announcement: Avenue Therapeutics' subsidiary, Baergic Bio, is set to be acquired by Axsome Therapeutics, which includes global rights to BAER-101, now known as AXS-17.
Development Focus: Axsome plans to evaluate AXS-17 as a potential treatment for epilepsy, gaining all commercial, development, and manufacturing rights along with existing clinical data.
Financial Terms: Baergic Bio shareholders will receive an upfront payment of $0.3 million, with potential milestone payments totaling up to $79 million and a tiered royalty on global net sales of AXS-17.
Future Payments: Avenue Therapeutics anticipates receiving approximately 74% of all future payments and royalties from the agreement with Axsome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
